Codexis, Inc. (CDXS)

Market Cap	152.23M
Revenue (ttm)	73.96M
Net Income (ttm)	-81.65M
Shares Out	69.83M
EPS (ttm)	-1.20
PE Ratio	n/a
Forward PE	138.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	407,332
Open	2.19
Previous Close	2.18
Day's Range	2.13 - 2.24
52-Week Range	1.45 - 6.98
Beta	1.87
Analysts	Buy
Price Target	11.00 (+400.0%)
Earnings Date	Nov 2, 2023

About CDXS

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 22, 2010
• Employees: 248
• Stock Exchange: NASDAQ
• Ticker Symbol: CDXS

Financial Performance

In 2022, Codexis's revenue was $138.59 million, an increase of 32.30% compared to the previous year's $104.75 million. Losses were -$33.59 million, 57.9% more than in 2021.

Analyst Forecast

According to 6 analysts, the average rating for CDXS stock is "Buy." The 12-month stock price forecast is $11.0, which is an increase of 400.00% from the latest price.

Price Target

$11.0

(400.00% upside)

Analyst Consensus: Buy